Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06764966 · ClinicalTrials.gov registry record · Phase 2
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
A Phase 2 study of Cirrhosis and Decompensated Cirrhosis of Liver, sponsored by CAMC Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06764966: Recruiting Phase 2 study of Cirrhosis and Decompensated Cirrhosis of Liver, sponsored by CAMC Health System.
NCT06764966 is a Phase 2 study of Cirrhosis and Decompensated Cirrhosis of Liver that is actively recruiting participants, run by CAMC Health System. The registered enrollment target is 50 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06764966, a Phase 2 study of Cirrhosis and Decompensated Cirrhosis of Liver, is actively recruiting participants, sponsored by CAMC Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is a critical need for strategies to delay progression to decompensation and reduce the occurrence of serious complications. Currently, limited therapeutic options are available for managing decompensated liver disease, with beta-blockers (BB) being the only proven medication with significant benefits in preventing disease progression. Statins have been historically under- prescribed in cirrhosis due to concerns of liver damage. However, there is emerging evidence that statin use may be beneficial and able to lessen liver disease worsening, with studies demonstrating its safety. Thus, we aim to conduct a pilot randomized controlled trial (RCT) study of 50 subjects comparing the outcomes of decompensated cirrhotic patients receiving the statin, atorvastatin, and a non-selective beta-blocker (NSBB) versus those receiving NSBB plus placebo. Both groups will be followed for 12 months to investigate the feasibility, safety, and efficacy of combination therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atorvastatin 20 mg
Study Locations (1)
West Virginia
- Charleston Area Medical Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What NCT06764966 shows while recruiting
NCT06764966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06764966 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT06764966 about?
NCT06764966 is a clinical study titled "Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis". Decompensated cirrhosis (liver disease) occurs when liver function decreases to the extent that serious complications develop and can include internal bleeding, fluid buildup in the abdomen, or mental confusion. This reduced decreased liver function subsequently decreases life expectancy. There is a...
What is the current status of trial NCT06764966?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-09-09. Estimated completion is 2027-03.
What conditions does trial NCT06764966 study?
This clinical trial studies the following conditions: Cirrhosis, Decompensated Cirrhosis of Liver, Decompensated Liver Cirrhosis, Decompensated Cirrhosis and Ascites.
What interventions are being tested in trial NCT06764966?
The interventions under investigation include: Placebo (DRUG), Atorvastatin 20 mg (DRUG).
Who is sponsoring clinical trial NCT06764966?
This trial is sponsored by CAMC Health System, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06764966 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06764966's enrollment target sits among peer trials
50 26th of 53 higher than 28 of 53 other Cirrhosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
-
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI